Hot Keywords
Tumor Microenvironment Exosomes and Extracellular Vesicles Breast Cancer Metastasis Bone Metastasis Metastatic Renal Cell Carcinoma Lymph node metastasis Mesothelioma Hematological Malignancies Thyroid Cancer Liquid Biopsies Early Diagnosis Lung Cancer Brain Tumors Lymphoma Oncolytic Virus Cervical Cancer Cancer Stem Cells

The paper's citation list
No.The paper's citation list
1Mesenchymal stem cells and prostate cancer: A concise review of therapeutic potentials and biological aspects. 2022;63:102864 doi: 10.1016/j.scr.2022.102864
2Interpretable machine learning for predicting pathologic complete response in patients treated with chemoradiation therapy for rectal adenocarcinoma. 2022;5: doi: 10.3389/frai.2022.1059033
3Markers of malignant prostate cancer cells: Golgi localization of α-mannosidase 1A at GM130-GRASP65 site and appearance of high mannose N-glycans on cell surface. 2020;527:406 doi: 10.1016/j.bbrc.2020.03.168
4Aldehyde Dehydrogenases and Prostate Cancer: Shedding Light on Isoform Distribution to Reveal Druggable Target. 2020;8:569 doi: 10.3390/biomedicines8120569
5Engineering Prostate Cancer from Induced Pluripotent Stem Cells—New Opportunities to Develop Preclinical Tools in Prostate and Prostate Cancer Studies. 2020;21:905 doi: 10.3390/ijms21030905
6Human Cell Transformation. 2019;1164:109 doi: 10.1007/978-3-030-22254-3_9
7Influence of Androgen Deprivation Therapy on the PD-L1 Expression and Immune Activity in Prostate Cancer Tissue. 2022;9: doi: 10.3389/fmolb.2022.878353
8Addressing cancer invasion and cell motility with quantitative light microscopy. 2022;12: doi: 10.1038/s41598-022-05307-7
9Epigenetic Control of Gene Expression in the Normal and Malignant Human Prostate: A Rapid Response Which Promotes Therapeutic Resistance. 2019;20:2437 doi: 10.3390/ijms20102437
10 ; ; ; doi:
11Biological Adaptations of Tumor Cells to Radiation Therapy. 2021;11: doi: 10.3389/fonc.2021.718636
12Cancer nanotechnology: current status and perspectives. 2021;8: doi: 10.1186/s40580-021-00282-7
© 2016-2023 OAE Publishing Inc., except certain content provided by third parties